Abstract
Purpose :
To report the 24-month results after one intravitreal ranibizumab (IVR) injection followed by pro re nata (PRN) dosing for macular edema (ME) after branch retinal vein occlusion (BRVO).
Methods :
The inclusion criteria included a minimal patient age of 18 years, 20 letters or more best-corrected visual acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] score, 77 letters or less), and central retinal thickness (CRT) of 250 microns or more. The primary outcome measure was the mean BCVA change from baseline at month 24; the secondary outcomes were mean changes in CRT, the number of IVR injections, and the rate of complete absorption of ME for longer than 6 months.
Results :
Twenty patients were enrolled from March 2014 through October 2016 at Nagoya City University Hospital. The baseline mean ETDRS letters and CRT were 62.0 and 511 microns, respectively; mean time from symptom onset to initial therapy, 1.80 months; and mean ETDRS gain and CRT reduction were 19.0 letters and 240 microns, respectively. The percentages of patients with Snellen equivalent BCVAs of 20/40 (70 ETDRS letters) or better and 20/20 (85 ETDRS letters) were 95% and 70%, respectively. The mean number of IVR injections was 8.3. Forty percent of patients did not need additional IVR injections for longer than 6 months during the follow-up. No adverse side effects were observed.
Conclusions :
Prompt initiation of IVR injection provided better visual prognosis at month 24. However, over 50% of the cases still had residual ME after 24 months.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.